Pulmonary Embolism Masquerading as High Altitude Pulmonary Edema at High Altitude

Prativa Pandey,1 Benu Lohani,2 and Holly Murphy1

Abstract

Pandey, Prativa, Benu Lohani, and Holly Murphy. Pulmonary embolism masquerading as high altitude pulmonary edema at high altitude. High Alt Med Biol. 17:353–358, 2016.—Pulmonary embolism (PE) at high altitude is a rare entity that can masquerade as or occur in conjunction with high altitude pulmonary edema (HAPE) and can complicate the diagnosis and management. When HAPE cases do not improve rapidly with descent, other diagnoses, including PE, ought to be considered. From 2013 to 2015, we identified eight cases of PE among 303 patients with initial diagnosis of HAPE. Upon further evaluation, five had deep vein thrombosis (DVT). One woman had a contraceptive ring and seven patients had no known thrombotic risks. PE can coexist with or mimic HAPE and should be considered in patients presenting with shortness of breath from high altitude regardless of thrombotic risk.

Keywords: extreme altitude; high altitude pulmonary edema; pulmonary embolism; thrombosis

Introduction

Acutemountain sickness (AMS), high altitude cerebral edema (HACE), and high altitude pulmonary edema (HAPE) occur with a frequency of 40%–50%, 1%–2%, and 0.2%–6% at altitudes greater than 4000 m (Hackett et al., 1976; Maggiorini, 2010). Pulmonary embolism (PE) at high altitude is a rare occurrence that is described only in case reports in the high altitude medicine literature (Nakagawa et al., 1993; Shlim and Papenfus, 1995; Ashraf et al., 2006). While AMS, HAPE, and HACE resolve with the oxygen-richer air of lower altitudes following descent (Hackett and Roach, 2001; Murdoch, 2004; Imray et al., 2010; Luks et al., 2014), the diagnosis of PE requires definitive treatment and, if missed, may result in death. Severe pulmonary arterial thrombosis and pulmonary infaracts were noted in autopsies of four of seven trekkers in the Himalayas (Dickinson et al., 1983) with the remaining three noted to have cerebral edema; two with brain herniation. Before death, all patients had a history and/or findings suggestive of severe altitude illness and PE was not suspected despite one patient being anticogulated after diagnosis of DVT. Reported death among trekkers from presumed altitude illness in Nepal ranges from 3.6 (Shlim and Gallie, 1992) to 7.7 per 100,000 trekkers (Leshem et al., 2008). It is possible that PE may have been responsible for some of these deaths.

Approximately 100,000 foreigners trek in Nepal annually (Nepal Tourism statistics 2014). From 2013 to 2015, over 1000 persons were seen at Canadian International Water and Energy Consultants (CIWEC) Clinic at 1400 m with altitude illnesses, including 217 with HACE and 303 with HAPE. Among 303 persons diagnosed with HAPE at initial presentation, 8 were shown to have PE by computed tomography pulmonary angiography (CTPA) and an equal number suspected of having PE had a negative CTPA. Pneumonia was suspected in 22 patients to co-exist with PE, whereas 3 persons were confirmed to have pneumonia as the primary diagnosis. We did not identify any patients in this cohort with congestive heart failure as the primary diagnosis though two persons with suspected HAPE had a final diagnosis of myocardial infarction based on ischemic changes on electrocardiogram (ECG) and diagnostic serum troponin elevations. Among all travelers seen at the CIWEC during the same period (24,000 for 3 years), PE was diagnosed in three cases without altitude exposure.

We describe and discuss in detail seven of the eight cases with PE diagnosed at our clinic. One of the eight patients declined to provide permission for reasons of privacy to be
included in this case series description. An evaluation of these cases may provide clues to PE diagnosis in the altitude traveler and hopefully to raise awareness of PE and DVT at high altitude.

Case No. 1

A 64-year-old British female was evacuated by helicopter from the Everest region with symptoms of dyspnea and cough in October 2013. She reported a relatively slow rate of ascent to Dingboche (4400 m) when she developed severe headache and nausea. She descended slowly by foot to Tengboche (3800 m) and then to Namche (3440 m) without symptom improvement. She noted fatigue and dyspnea on exertion (DOE) with a few steps. She denied any significant past medical history and was not taking any medication. Upon arrival to the CIWEC, her SpO₂ was 99% on ambient air though she remained dyspneic with a respiratory rate (RR) of 26 breaths per minute. Her lungs were clear to auscultation, and chest X-ray was unremarkable. She was thought to have residual HAPE and was administered O₂. An echocardiogram showed mild mitral regurgitation (MR), mild tricuspid regurgitation (TR), and mild elevation of the systolic pulmonary artery pressure with no dilatation of right atrium (RA) or right ventricle (RV). In light of her persistent dyspnea, 24 hours after admission, a CTPA was done that documented thrombi in the right pulmonary artery and segmental branches of bilateral lower lobe pulmonary arteries (Fig. 1). Patchy consolidation was noted in the right middle lobe. Doppler studies showed normal deep veins in both lower limbs. She was treated with oxygen and anticoagulation and discharged with a therapeutic International Normalized Ratio (INR) after 6 days.

Case No. 2

A 62-year-old Swiss male climbing in the Manaslu region of Nepal in October 2013 developed pain and heaviness in the left calf 18 days into the trip at 6100 m. Four days later, he developed chest pains and dyspnea upon further ascent. He was evacuated by helicopter to CIWEC where he noted mild improvement in his respiratory symptoms. He had no significant past medical history and was not taking any medication. His SpO₂ on ambient air was 89%; the lungs were clear and left leg swelling was noted. Electrocardiogram (ECG) showed nonspecific changes in the inferior leads and blood studies revealed normal troponin and creatinine kinase MB (CK-MB) isoenzyme concentrations. Polycythemia was noted with hematocrit of 54.8%; but all other laboratory studies were unremarkable. Doppler ultrasound confirmed DVT in the left popliteal and posterior tibial veins. His CTPA revealed thrombi in superior and inferior segments of right main pulmonary artery and bilateral lower lobe arteries (Fig. 2). Cardiac ultrasound showed mitral valve prolapse (MVP), mild MR, and trivial TR. The RV and RA were not dilated. There was no obvious thrombus visualized at the pulmonary artery (PA) bifurcation. He was treated with oxygen and anticoagulation and discharged after 5 days.

Case No. 3

A 53-year-old American male was evacuated by helicopter from the Everest region in October 2013. He had a history of hypertension, hypercholesterolemia, and bilateral hip surgeries (2 and 6 years prior). He had kept to a relatively slow ascent rate after a flight to Lukla (2800 m) and with appropriate acclimatization before trekking to Khumjung and the Kongde Ridge (4250 m). He noted severe bilateral hip pain and cold from a drafty room, thus sleeping on an electric mattress intermittently for 16 hours. By morning, he noted dizziness and fell without sustaining any trauma due to a brief loss of consciousness. He also complained of DOE. He received oxygen and oral hydration prior to evacuation to Kathmandu by helicopter. Upon arrival, he was diaphoretic, tachycardic, and hypotensive (pulse 120/min, blood pressure [BP] 90/80 mm Hg, RR 24/min) with a SpO₂ of 77% on ambient air, but felt some symptomatic improvement with the descent. His lungs were clear, and cardiac examination was normal. There was no leg swelling or tenderness.

Laboratory evaluation revealed leukocytosis, renal insufficiency, and hyponatremia (White cell count 17,800/mm³, hematocrit 43.2%, BUN 20.4 mg/dL, serum creatinine 1.6 mg/dL, sodium 129 meq/L, potassium 3.4 meq/L, glucose 186 mg/dL). His chest radiograph was unremarkable. ECG

FIG. 1. Patient 1: Axial image of computed tomography (CT) pulmonary angiogram with filling defect in right pulmonary artery (arrow) indicating thrombus.

FIG. 2. Patient 2: Axial image of CT pulmonary angiogram showing thrombi as filling defects in distal right pulmonary artery (arrow) with extension into right lower lobe branches.
was discharged after 5 days. A Doppler study revealed an acute DVT in the left popliteal vein. He was treated with oxygen and anticoagulation and discharged after 8 days.

Case No. 4

A 37-year-old German female presented in November 2013 with right leg pain for 3 days upon completion of a trek to the Everest region. She reported dyspnea and a dry cough at 4900 m. She was evacuated by horse to 2800 m with subsequent helicopter evacuation to Kathmandu. She was using a combined contraceptive vaginal ring (NuvaRing). She denied cigarette smoking. Presenting vital signs at the CIWEC were unremarkable (temperature 37.5°C, pulse 97/min, BP 110/80 mmHg, SpO2 98% on ambient air) as were her lung and cardiac examinations. Edema and tenderness were noted in the right calf. She reported a slightly larger right calf at baseline due to a congenital large vascular nevus. Doppler ultrasound demonstrated an acute DVT extending along the mid one-third of the femoral vein proximally. Her ECG and echocardiogram were unremarkable. Her CTPA showed multiple thrombi in the sub-segmental branches of the right upper and both lower lobe pulmonary arteries. She was treated with oxygen and anticoagulation, and the contraceptive vaginal ring was removed.

Case No. 5

A 70-year-old American male was trekking in the Langtang region in April 2013, 4 days after arriving in Nepal. He reported fatigue, cough, and dyspnea 4 days into the trek. He was evacuated to Kathmandu by helicopter from Magin Goth (3285 m). On arrival, he was dyspneic and afebrile with a RR 30/min and SpO2 70% on ambient air, pulse 82/min, BP 130/80 mmHg. There were scattered crepitations in both lung bases. His white cell count was within normal limits. His echocardiogram showed mild TR, mildly elevated pulmonary artery pressure, and a mildly dilated RV. The chest X-ray showed non-homogeneous opacities in the mid and lower zones of both lungs with PA enlargement interpreted as consistent with HAPE. He received oxygen, amoxicillin–clavulanic acid, and azithromycin. He remained dyspneic requiring oxygen for more than 24 hours. A CTPA was done on the following day revealing thrombi in the segmental artery of right lower lobe. A Doppler study revealed an acute DVT involving the left popliteal vein. He was treated with oxygen and anticoagulation and discharged after 8 days.

Case No. 6

A previously healthy 71-year-old Austrian woman was evacuated from the Everest region from 4900 m on horseback to 4200 m due to severe respiratory distress and decreased responsiveness. Soon after arrival to the medical aid-post, she lost consciousness and pulses, and developed agonal breathing. She was treated with high flow oxygen, IV fluids, and dexamethasone with minimal improvement overnight, and remained somnolent with labored breathing at which point she was evacuated to Kathmandu. On arrival at the CIWEC, she was conscious, but dyspneic with RR at 32/min, pulse—100/min, temp—37.9°C, and SpO2 of 78%. Her lungs were clear, and cardiac examination was normal. The ECG showed T wave inversions in lead V1–3. Her CXR was normal and echocardiogram showed dilated RA/RV, mild TR, and mild elevation of the systolic pulmonary artery pressure. A CTPA confirmed thrombosis in the right and left pulmonary arteries and in their inferior and superior branches. Doppler ultrasound of both legs showed a normal deep venous system in both lower limbs with the exception of a superficial acute thrombosis in the right calf. She was treated with anticoagulation, oxygen, and was discharged to return to her home country.

Case No. 7

A 49-year-old German male trekker was seen after helicopter evacuation from 4700 m 11 days into his trek. He developed dyspnea at an altitude of 4100 m, but was able to continue and cross the Teri La pass in Mustang at 5600 m. He developed increasing dyspnea, fatigue, cough, and intermittent chest pain despite descent to 4700 m and was helicopter evacuated to Kathmandu. At the CIWEC, he was tachypneic on arrival with other vital signs stable (RR 28–30/min, SpO2 96%, pulse 77/min, and temp of 37.1°C). There were bibasilar crepitations in the lungs, and the cardiac examination was normal. An ECG showed antero-lateral T wave inversions, the echocardiogram showed dilated RA and RV, trace TR with mildly elevated systolic PA pressure. His CTPA showed multiple thrombi in the sub-segmental branches of the right upper and both lower lobe pulmonary arteries. Doppler ultrasound of both lower extremities demonstrated acute thrombosis of the deep veins of the left calf with extension into the posterior tibial veins. He improved with oxygen and anticoagulation.

Summary

We present seven of the eight cases with preliminary diagnosis of HAPE who did not improve with descent and
oxygen as expected and were diagnosed with PE following definitive imaging studies. The average age of the cases with PE was significantly older than that for HAPE in the same period at the CIWEC: 58 years (range 37–71 years) versus 45 years (range 20–74 years). Six of seven cases had been to altitudes ≥4000 m (Table 1). Five of seven patients developed symptoms after 10 or more days trekking at high altitude. Five of our PE cases were found to have DVT and one case had calf vein thrombosis on compression ultrasonography (Table 1).

Discussion

While HAPE is a common problem at high altitude in Nepal with rates of 1%–6% reported in the Everest region alone (Hackett et al., 1976; Basnyat et al., 1999), PE has been uncommonly reported among trekkers and climbers to Nepal (Dickinson et al., 1983; Shlim and Papenfus, 1995). Despite the current knowledge of altitude and pulmonary disease and scattered case reports, there is no clear association between PE risk and altitude. There are some data suggesting an increased risk among individuals with underlying coagulopathy (Schreijer et al., 2006; Khalil and Saeed, 2010). There are larger retrospective studies suggesting a prolonged stay at altitude alone may be a risk for PE (Anand et al., 2001; Khalil and Saeed, 2010; Rathi et al., 2012), but these data do not suggest greater risks for shorter stays, for example, of the trekker/mountaineer. Considering the lack of clear association between altitude and PE and the prevalence of HAPE as a cause of respiratory distress from altitude, there is often great difficulty in deciding which patients to evaluate for PE in this setting.

PE at altitude in our series is likely multifactorial—including modifiable and unanticipated factors—and may present in altitude travelers without prior risk factors. Despite the lack of evidence that short-term travel to altitude increases PE risk, there are aspects of altitude excursions that increase blood viscosity, for example, dehydration causing hemoconcentration, and polycythemia, in addition to the compensatory rise in hematocrit with acclimatization, which are likely to increase PE risk. In our series, one patient was noted to have polycythemia. Though a prolonged journey prior to trekking poses an obvious risk, most of the patients presented here developed symptoms late in their trek suggesting that this was not a risk factor. Only one elderly traveler who developed respiratory symptoms at lower altitude (3200 m) had trekked within 7 days of an international flight, suggesting that short time interval after his flight may have been a risk in this case. Furthermore, we have noted 3 fold more PE cases occurring with altitude than at lower altitude in the last 3 years. The majority of these cases at altitude became ill above 4000 m, which may support prior work suggesting a role for increasing altitude in thrombosis (Gupta and Ashraf, 2012). Still, none of these factors distinguish PE from HAPE.

The average age of our PE cases was significantly higher than that for HAPE patients. The risk of phlebitis and PE has been shown to be higher for age ≥60 versus younger travelers (Gautret et al., 2012). However, selecting patients for evaluation simply based on age would still result in missed PE diagnoses, considering three of seven patients in this series were less than 55. In this series, only one patient had a known thrombotic risk—vaginal contraceptive ring, which has similar prothrombotic risk as combined oral contraceptives (Kolacki and Rocco, 2012; Nguyen and Jensen, 2014; Kenmuir et al., 2015; Paresi et al., 2015). Based on this and prior reports (Shlim and Papenfus, 1995; Schreijer et al., 2006; Khalil and Saeed, 2010), we conclude that any thrombotic risk factor should warrant a PE work-up for hypoxemia and any respiratory symptoms or findings at high altitude.

Initial clinical, laboratory, and radiographic presentation provided clues to the PE diagnosis in the 2 cases with DVT symptoms (Cases 2 and 4) and for 1 patient (Case 3) who was hypotensive and hypoxic on arrival with a negative
cardiac workup and normal chest X-ray. Another four were persistently dyspneic after descent and therefore underwent CTPA. Other data—including ECG, CXR, and echocardiogram findings among these patients did not vary significantly from patients with “pure” HAPE. The clinical assessment tools e.g. the Wells criteria that take into account recent surgery, immobility, and presence of malignancy were not useful in identifying risk among these patients (Wells et al., 2000). We do not screen patients with HAPE with D-dimer testing despite the high sensitivity (Righini et al., 2014; Woller et al., 2014) due to the low specificity that can lead to unnecessary imaging studies, which may also introduce further hazard to the hypoxic patient (Rathi et al., 2012; Bokobza et al., 2014). Furthermore, there is evidence that D-dimer levels increase with altitude in the absence of overt thrombosis (Pichler Hefti et al., 2010). We are not aware that we missed any cases of significant PE with this approach. We conclude that a thorough clinical evaluation and high index of suspicion if the response to HAPE treatment is poor remains our most sensitive diagnostic strategy for considering PE in this setting.

Theoretically, systemic endothelial dysfunction—recently shown to occur in HAPE cases with finding of raised endothelin-1 (ET-1) levels (Droma et al., 1996; Sartori et al. 1999; Berger et al. 2005; Charu et al., 2006; Barker et al., 2016), may also be elevated with PE. Efforts to identify rapid tests for HAPE will need to differentiate between these potentially overlapping and confounding diagnoses.

We conclude that PE, a diagnosis with significant mortality, may be missed in the traveler at high altitude due to similar presenting symptoms as occur with HAPE. Based on our experience, including the cases presented here, we propose obtaining a CPTA or other imaging such as a nuclide ventilation-perfusion scan when patients presenting with symptoms suggestive of HAPE who do not improve or get worse with descent within 24 hours. Moreover, diagnostic imaging should be considered if a DVT is suspected when symptoms develop during descent, and when significant chest pain is present and other etiologies such as myocardial infarction are ruled out and lastly for patients with any known or perceived thrombotic risk. Due to the high fatality of PE and the overlap in clinical presentation with HAPE, a more aggressive approach to PE diagnosis is warranted in high altitude travelers with respiratory symptoms.

Acknowledgments
The authors thank Dr. Shreeyukta Bhattarai and Dr. Raksha Shrestha for their assistance in article preparation.

Author Disclosure Statement
No competing financial interests exist.

References
Anand AC, Jha SK, Saha A, Sharma V, and Adya CM. (2001). Thrombosis as a complication of extended stay at high altitude. Natl Med J India 14:197–201.
Ashraf HM, Javed A, and Ashraf S. (2006). Pulmonary embolism at high altitude and hyperhomocysteinemia. J Coll Physicians Surg Pak 16:71–73.
Barker KR, Conroy AL, Hawkes M, Murphy H, Pandey P, and Kain KC. (2016). Biomarkers of hypoxia, endothelial and circulatory dysfunction among climbers in Nepal with AMS and HAPE: A prospective case-control study. J Travel Med 23:1–7.
Basnyat B, Savard GK, and Zafren K. (1999). Trends in the workload of the two high altitude aid posts in the Nepal Himalayas. J Travel Med 6:217–222.
Berger MM, Hesse C, Dehnert C, Siedler H, Kleinbongard P, Bardenheuer HJ, Kelm M, Bartsch P, and Haefeli WE (2005). Hypoxia impairs systemic endothelial function in individuals prone to high-altitude pulmonary edema. Am J Respir Crit Care Med 172:763–767.
Bokobza J, Aubry A, Nakle N, Vincent-Cassy C, Pateron D, Devilliers C, Riou B, Ray P, and Freund Y. (2014). Pulmonary embolism rule-out criteria vs D-dimer testing in low-risk patients for pulmonary embolism: A retrospective study. Am J Emerg Med 32:609–613.
Charu R, Stobdan T, Ram RB, Khan AP, Qadar Pasha MA, Norboo T, and Afrin F. (2006). Susceptibility to high altitude pulmonary oedema: Role of ACE and ET-1 polymorphisms. Thorax 61:1011–1012.
Dickinson J, Heath D, Gosney J, and Williams D. (1983). Altitude-related deaths in seven trekkers in the Himalayas. Thorax 38:646–656.
Droma Y, Hayano T, Takabayashi Y, Koizumi T, Kubo K, Kobayashi T, and Sekiguchi M. (1996). Endothelin-1 and interleukin-8 in high altitude pulmonary oedema. Eur Respir J 9:1947–1949.
Gautret P, Gaudart J, Leder K, Schwartz E, Castelli F, Lim PL, Murphy H, Keystone J, Cramer J, Shaw M, Boddart J, von Sonnenburg F, Parola P, and GeoSentinel Surveillance Network. (2012). Travel-associated illness in older adults (>60 y). J Travel Med 19:169–177.
Gupta N, and Ashraf MZ. (2012). Exposure to high altitude: A risk factor for venous thromboembolism? Semin Thromb Hemost 38:156–163.
Hackett PH, Rennie D, and Levine HD. (1976). The incidence, importance, and prophylaxis of acute mountain sickness. Lancet 2:1149–1155.
Hackett PH, and Roach RC. (2001). High-altitude illness. N Engl J Med 345:107–114.
Imray C, Wright A, Subudhi A, and Roach R. (2010). Acute mountain sickness: Pathophysiology, prevention, and treatment. Prog Cardiovasc Dis 52:467–484.
Kenmuir CL, Jovin T, and Jadhav A. (2015). Cerebral venous sinus thrombosis in users of a hormonal vaginal ring. Obstet Gynecol 126:830–833.
Khalil KF, and Saeed W. (2010). Pulmonary embolism in soldiers serving at high altitude. J Coll Physicians Surg Pak 20:468–471.
Kolacki C, and Rocco V. (2012). The combined vaginal contraceptive ring, nuvaring, and cerebral venous sinus thrombosis: A case report and review of the literature. J Emerg Med 42:413–416.
Leshem E, Pandey P, Shlim DR, Hiramatsu K, Sidi Y, and Schwartz E. (2008). Clinical features of patients with severe altitude illness in Nepal. J Travel Med 15:315–322.
Luks AM, McIntosh SE, Grissom CK, Auerbach PS, Rodway GW, Schoene RB, Zafren K, Hackett PH, and Wilderness Medical Society. (2014). Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update. Wilderness Environ Med 25(4 Suppl):S4–S14.
Maggiorni M. (2010). Prevention and treatment of high-altitude pulmonary edema. Prog Cardiovasc Dis 52:500–506.
Murdock DR. (2004). Prevention and treatment of high-altitude illness in travelers. Curr Infect Dis Rep 6:43–49.
Nakagawa S, Kubo K, Koizumi T, Kobayashi T, and Sekiguchi M. (1993). High-altitude pulmonary edema with pulmonary thromboembolism. Chest 103:948–950.

Nguyen BT, and Jensen JT. (2014). Evaluating the efficacy and safety of a progestin- and estrogen-releasing ethylene vinyl acetate copolymer contraceptive vaginal ring. Expert Opin Drug Saf 13:1423–1430.

Paresi RJ, Jr., Myers RS, and Matarasso A. (2015). Contraceptive vaginal rings: Do they pose an increased risk of venous thromboembolism in aesthetic surgery? Aesthet Surg J 35:721–727.

Pichler Hefti J, Risch L, Hefti U, Scharrer I, Risch G, Merz TM, Turk A, Bosch MM, Barthelmes D, Schoch O, Maggiorini M, and Huber AR. (2010). Changes of coagulation parameters during high altitude expedition. Swiss Med Wkly 140:111–117.

Rathi K, Uppal V, Bewal N, Sen D, and Khanna A. (2012). D-dimer in the diagnostic workup of suspected pulmonary thrombo-embolism at high altitude. Med J Armed Forces India 68:142–144.

Righini M, Van Es J, Den Exter PL, Roy PM, Verschuren F, Guhyesen A, Rutschmann OT, Sanchez O, Jaffrelot M, Trinh-Duc A, Le Gall C, Moustafa F, Principe A, Van Houten AA, Ten Wolde M, Douma RA, Hazelaar G, Erkens PM, Van Kralingen KW, Grootenboers MJ, Durian MF, Cheung YW, Meyer G, Bounaumeaux H, Huisman MV, Kamphuisen PW, and Le Gal G. (2014). Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: The ADJUST-PE study. JAMA 311:1117–1124.

Sartori C, Vollenweider L, Loffler BM, Delabays A, Nicod P, Bartsch P, and Scherrer U. (1999). Exaggerated endothelin release in high-altitude pulmonary edema. Circulation 99:2665–2668.

Schreijer AJ, Cannegieter SC, Meijers JC, Middeldorp S, Buller HR, and Rosendaal FR. (2006). Activation of coagulation system during air travel: A crossover study. Lancet 367:832–838.

Shlim DR, and Gallie J. (1992). The causes of death among trekkers in Nepal. Int J Sports Med 13 Suppl 1:S74–S76.

Shlim DR, and Papenfus K. (1995). Pulmonary embolism presenting as high-altitude pulmonary edema. Wilderness Environ Med 6:220–224.

Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, and Hirsh J. (2000). Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: Increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 83:416–420.

Woller SC, Stevens SM, Adams DM, Evans RS, Lloyd JF, Snow GL, Bledsoe JR, Gay DZ, Patten RM, Aston VT, and Elliott CG. (2014). Assessment of the safety and efficiency of using an age-adjusted D-dimer threshold to exclude suspected pulmonary embolism. Chest 146:1444–1451.

Address correspondence to:

Prativa Pandey, MD
CIWEC Hospital
PO Box 12895
Kathmandu 44600
Nepal

E-mail: prativap@gmail.com

Received January 28, 2016; accepted in final form September 10, 2015.